DSIP protocols in the published literature

Is there an established DSIP dose for a person?

review

No established human dosing schedule for DSIP appears among the research behind this page. Three investigations gave it to people and recorded their sleep, all of them in the 1980s, and every one delivered it into a vein in a sleep laboratory.

A handful of infusions is not a protocol. A 1997 review of neuropeptides and human sleep concluded that the impact of delta sleep-inducing peptide, cholecystokinin, and thyrotropin-releasing hormone on human sleep regulation is not yet clear.1 Three decades later, a 2026 review grouping DSIP with other recovery peptides still reports a current lack of clinical trials.2

The honest answer to how much, then, is that the question was put a few times under medical supervision, with material made for a laboratory, and then dropped rather than followed up.

What did the human sleep investigations actually administer?

human pilot / early trial

All three went into a vein, and the setting matters as much as the amount given. The earliest tested acute intravenous administration of synthetic DSIP in 6 middle-aged chronic insomniacs in 1981.3 A 1984 paper then summarizes different investigations into effects of delta sleep-inducing peptide (DSIP) injections on insomnia.4 Several of those gave a single injection before sleep.

The 1987 study is the only one with a control group. There, a placebo was administered i.v. during four nights using a double-blind crossover design, and no significant differences were found in comparison to baseline or to double-blind placebo nights.5

Each of them worked the amount out from body weight, and this page does not restate those figures, because a number taken off a 1980s hospital drip is not a schedule for an unlabelled vial. A 1993 hormone experiment in healthy women reported working at dosages which are known to modify ECG patterns, meaning the electrical trace of the heartbeat, so these were not token amounts.6

What amounts did the animal sleep experiments use?

animal model

The animal papers are where the figures live, and each one is tied to a species and a route. A 1984 report gave rabbits 25 micrograms per kilogram into a vein and 1 milligram per kilogram under the skin, which is a forty-fold gap between two routes in one experiment.7 The same report gave cats 25 micrograms per kilogram into a vein and 100 micrograms per kilogram under the skin.7

Mice were given 25.5 micrograms per kilogram into a vein, while under the skin it took doses beyond 85 micrograms per kilogram.7 Across those experiments the route moved the figure much further than the species did.

An earlier Swiss series had already found that intravenous administration of DSIP was shown to produce, in different animals, sleep lasting for hours.8 That finding came from laboratory animals on a drip rather than from people holding a syringe.

What amounts appear in the experiments that were not about sleep?

animal model

Much of this literature measured something other than sleep, and those papers hold the largest quantities. A 1995 Russian stress experiment used rats which received DSIP in a dose of 60 nmol/kg one hour before decapitation.9 Nanomoles per kilogram counts molecules rather than weighing them, so those figures cannot be read against a microgram measurement.

A 1984 experiment infused a fixed quantity straight into the fluid spaces of the brain. Delta-sleep-inducing peptide (2.5 nmol), prostaglandin D2 (0.36 nmol) and uridine (10 pmol) were intraventricularly infused for 10 h at daytime in otherwise saline-infused freely moving male rats, with body weight entering nowhere.10

The seizure experiments ran larger again. Metaphit-treated rats displaying seizures in 8 previous tests were i.p. injected with VPA (50 mg/kg) or DSIP (1.0 mg/kg) or their combination, an injection into the belly cavity.11 A companion paper reported that ED50 of valproate in the 1st hour after administration was 63.19 mg kg(-1) and that of DSIP 3.19 mg kg(-1) four hours after injection, with ED50 meaning the amount that worked in half the animals.12

Why do the published DSIP amounts not line up?

animal model

Because the dose-response relationship is not a ladder. A 1984 review of the whole literature records that a U-shaped activity curve was determined for the dose as well as for the time of infusion, meaning the middle of the range did less than either end of it.13

The clearest case is a mouse experiment on body temperature. The authors examined this effect in mice with 9 different concentrations of DSIP in addition to D-Ala4-DSIP and an analog, DSIP-P, phosphorylated at the serine in position 7.14 The effect was only significant after pretreatment with 0.1 and 150 nmol DSIP/kg, but not the other doses.14

Read that carefully: it is the most useful line on this page. Two amounts a long way apart did something in mice, and every amount between them did nothing. The authors concluded that complex dose-effect relationships seem to exist for DSIP (and perhaps its analogs) in thermoregulation.14 A ladder assumes that more is more, and this animal work says otherwise in both directions.

Does the route change how much is needed?

animal model

It changes it more than any other variable in this literature. The group that isolated the peptide reported that I.c.v., i.v. and s.c. administration yielded, in contrast to pharmaka, a parabolic dose-response curve with different effective optima.8 Those abbreviations mean into the brain fluid, into a vein and under the skin, pharmaka means ordinary drugs, and different effective optima means every route had its own separate peak. The rat seizure experiments introduced a fourth route again: the rats divided in four groups received (i.p.): saline; metaphit; metaphit+DSIP; and metaphit+DSIP-12, respectively.15 Underneath all of this sits how little crosses from the blood into the brain. A 1983 review of peptides and the blood-brain barrier places DSIP in a short list. Some peptides, such as insulin, delta-sleep-inducing peptide, and the lipotropin-derived peptides, enter the cerebrospinal fluid to a slight or moderate extent in the intact form16.

What is a DSIP dosing chart actually built from?

animal model

A dosing chart implies a ladder: a starting quantity, an increment, a frequency to maintain. The published record is not organised like that, so a chart must be taking its rungs from somewhere else.

An accurate version would carry four columns — species, route, quantity, outcome measured — and most of its rows would say rabbit, rat or mouse. Several of the largest quantities come from seizure and stress experiments in rats, where no sleep stage was recorded.

It would also have to represent the shape of the response. In most experimental situations, indications for bell-shaped dose-response curves of DSIP were found, which is a finding no single row can accommodate.7 And the last column would be nearly empty: a 2026 review of peptides in orthopaedics reports a current lack of clinical trials for the recovery peptides it groups DSIP with.2

How often was DSIP given, and for how long?

human pilot / early trial

The courses here are short, and the longest of them are in animals. In the human insomnia work, repeated administrations indicated a buildup with normalization of sleep structure after four administrations, which is the only published sign of repeated dosing accomplishing something a single dose did not.4

The controlled study ran four nights in a row and found nothing against placebo on its main comparisons.5 Four consecutive nights is the longest human course among these sources, and it cannot answer a question about four weeks.

A 2021 stroke experiment concluded that intranasal administration of DSIP in the course of 8 days leads to accelerated recovery of motor functions in rats.17 Eight days in a rat recovering from an experimental stroke is a considerable distance from a nightly routine in a person.

Does DSIP need to be cycled?

human pilot / early trial

No study among the research behind this page examined a break, a taper or a cycle. The nearest approximation is an observation from 1984: repeated injections in the morning — besides increasing daytime activity — still had a strong positive effect on night sleep, but not so two doses daily.4

Read that carefully, because it runs against the usual shape of the cycling question. Twice daily performed worse than once daily, so what failed was more frequent administration rather than continuous administration. The same summary records that a case of insomnia in organic brain disease responded well to higher doses, which is one patient rather than a pattern of any kind.4

A cycling schedule assumes an effect that fades under steady use and returns after a break, and neither half of that was ever measured among these sources. The 1984 review also found a U-shaped curve for the time of infusion as well as for the amount, so timing was already behaving oddly in the animal work.

What is published about nasal and oral DSIP?

animal model

One experiment, conducted in rats, concerning a stroke. DSIP or vehicle was applied nasally 60 (±15) minutes prior to the occlusion and for 7 days after reperfusion at dose 120 µg/kg, and the researchers subsequently measured motor coordination rather than sleep.17

That experiment constitutes the entire nasal record among these sources. A spray marketed for sleep is invoking a route examined once, in a rodent surgical model, at a quantity set per kilogram of rat.

Swallowing it has even less behind it. A 1984 characterisation reports that the penetration of the blood-brain barrier by the peptide has been proven and it was shown that unweaned rats are able to take up DSIP by the intestinal tract.8 Unweaned rats absorb intact proteins from milk in a manner adult mammals do not, so that sentence describes infant rodent digestion rather than an adult swallowing a capsule.

How does a 5 mg or 10 mg vial relate to the published work?

animal model

It does not, and that is worth saying plainly. Vial sizes are packaging decisions, while every figure in the research behind this page is either calculated per kilogram of animal body weight or infused as a fixed amount into a rat's brain. None of them is written as a fraction of a vial.

The older animal work raises a second question about a vial. In those animal experiments, analogs with exchanged amino acids in the sequence or shortening the peptide by one or two amino acids decreased or abolished the effect, as did breakdown products, suggesting a close structure-specificity.8

That matters more than the number on a label, because the effect in rabbits and rodents depended on the intact nine-amino-acid chain, while near-misses and fragments did less or nothing. A vial is a claim about identity before it is a claim about amount.

How does the reconstitution arithmetic work?

This part is arithmetic, and it is the same for any freeze-dried powder. The label gives a mass of powder, you add a volume of liquid, and what comes out of that is a concentration. Milligrams times one thousand gives micrograms, and micrograms divided by the millilitres you added gives micrograms per millilitre.

The syringe does the second half, and a U-100 insulin syringe is marked in units, one hundred of which fill a single millilitre, so one unit on the barrel holds a hundredth of a millilitre. Our reconstitution calculator runs the same arithmetic, and it suggests no target.

One conversion trap belongs to this literature in particular. Much of the older work is recorded in nanomoles and picomoles, which count molecules instead of weighing them, and those figures do not turn into micrograms without the molecular weight of the peptide. The older figures cannot be read straight across to a modern label.

What is not known about DSIP amounts

The gap is the middle of the subject rather than a detail. No study among the research behind this page compared two different amounts in people, so whether more accomplishes more was never submitted to a test.

There is no modern replication among these sources either. The human sleep work ran between 1981 and 1987, all of it by infusion into a vein, and the reviews published since have left that picture unresolved rather than settled. No amount under the skin for a person appears among these sources, which is precisely the route most readers are asking about.

The animal record cannot substitute, because of the shape of the curve: a response that peaks twice and collapses in the middle cannot be scaled from a rabbit to a person by body weight. What the literature supports is a record of which amount went into which animal by which route, and the plain statement that the matching human figure was never established.